-
The core assets of the pharmaceutical sector gradually stabilized, and many stocks rose by the limit on September 6
Time of Update: 2022-05-04
The core assets of the pharmaceutical sector have gradually stabilized Analysis of the daily limit of Essence Pharma on September 6 On September 6, Essence Pharma closed at the daily limit, with a closing price of 6.
It is reported that the stock is a hot stock of PD-1 inhibitor, traditional Chinese medicine, and medical concept.
-
This insulin concept stock has a daily limit, and the market outlook may continue to increase its momentum
Time of Update: 2022-05-04
It is reported that Gan & Lee Pharmaceuticals will expand overseas markets to offset the risk of price reductions after insulin is included in centralized procurement .
-
The pharmaceutical sector rose in September, and three pharmaceutical companies rose by more than 40%
Time of Update: 2022-05-04
The data shows that in the first half of the year, the sales volume of Weir Pharmaceutical's pharmaceutical excipient products increased by 2.
The net profit is expected to exceed 200 million yuan after the fundraising project reaches production .
-
The pharmaceutical and biological sectors are among the top gainers, with Xingqi eye medicine and Tongce Medical rising one after another
Time of Update: 2022-05-04
The 2021 interim report shows that the company's net profit in the first half of the year was 914 million yuan, a year-on-year increase of 19 times .
Tongce Medical rose rapidly in the intraday market, with an increase of more than 2% within 5 minutes.
-
How much room for future growth of kudzu root, which has been at a low price for many years?
Time of Update: 2022-05-02
Due to the limited production this year, merchants are concerned about price changes in the market outlook .
After the beginning of the year, the supply of goods is moving smoothly, and the market continues to rise slightly .
-
The new national regulations on mutual recognition of inspection results are here!
Time of Update: 2022-05-02
Article 6 The local health administrative departments shall strengthen the organization and management of medical institutions within their respective jurisdictions, guide medical institutions and their medical staff to standardize the mutual recognition of inspection and test results, and strengthen the construction of regional platforms in accordance with the requirements of the functional guidelines for the construction of national health information platforms.
-
With many crises, how can small and medium-sized chains use their teams to spell out "new competitiveness"?
Time of Update: 2022-05-02
. For small and medium-sized chains, passenger flow is also a pain point, and passenger flow is closely related to price, brand, variety, and service .
-
Follow-up of national procurement violations: hospital returns and replacement companies sign new contracts!
Time of Update: 2022-05-02
Hainan issued alternate work arrangements On February 18, the Hainan Provincial Public Resource Trading Service Center issued the "Notice on Determining the Second Batch of Nationally Organized Drug Collection Varieties Glimepiride Tablets for Substitute Supply Enterprises in Hainan Province".
-
The whole process of traditional Chinese medicine decoction pieces can be traced back to local pilot non-traceable decoction pieces or gradually abandoned
Time of Update: 2022-05-02
Recently, Shanghai issued the "Notice on Carrying out the Pilot Work of Clinical Application of Whole-process Traceability of Traditional Chinese Medicine Pieces in the City", selected 5 well-known Chinese medicine hospitals and 8 pharmaceutical companies in Shanghai as pilots, supported the use of traceable pieces, and encouraged high quality and good prices.
-
The focus of the 2022 National Primary Health Conference is here
Time of Update: 2022-05-02
In August of the same year, the National Health and Medical Commission issued the "Notice on Launching the Construction of a Comprehensive Pilot Zone for Grass-roots Health and Health", which clearly stated that it should be supported by cultivating multi-disciplinary talents with medical, preventive, and management capabilities and information technology to further promote grass-roots chronic diseases.
-
Looking at the new development trend of China's pharmaceutical industry from the new rules of the Yangtze River Delta Alliance
Time of Update: 2022-05-01
On February 25, the Centralized Drug Purchasing Working Group of the Yangtze River Delta (Shanghai, Zhejiang and Anhui) Alliance released the declaration information through video, which means that t
-
Osaikang has accumulated a lot, and the first class 1 new drug is benchmarked against 4 billion varieties!
Time of Update: 2022-05-01
Table 1: Category 1 new drugs declared by Osaikang since 2020 Source: Minet database, CDE official website ASK120067 tablet is a third-generation EGFR inhibitor targeting T790M for the treatment of non-small cell lung cancer, Osaikang in 2017 After obtaining the clinical approval in 2019, the company obtained the CDE license in 2019 based on the outstanding results of the Phase I/II clinical study.
-
Recently, the price of many commonly used drugs has been reduced, the gross profit of the drug retail industry has declined, and the status of pharmacies has risen
Time of Update: 2022-05-01
In addition to Lianhua Qingwen, the notice also announced a specific list of 19 drug price reductions, involving aspirin enteric-coated tablets and Shenshuining capsules commonly sold in pharmacies .
-
The target layout is low in homogeneity and the market competition pattern is good
Time of Update: 2022-05-01
In response to the mismatch between light and heavy chains, bispecific antibody R&D companies have developed different technical platforms for IgG and non-IgG double antibodies.
-
BeiGene's 22 Class 1 New Drugs Are Eye-catching, Over 10 New Drugs "Going Overseas to Take the Test"
Time of Update: 2022-05-01
In terms of internationalization, BeiGene has set a record for the highest amount of authorized cooperation for a single product in China, and more than 10 self-developed innovative drugs have been clinically launched overseas, of which zanubrutinib has achieved a "zero breakthrough" .
-
Why did the legendary CAR-T succeed?
Time of Update: 2022-05-01
On February 28, local time, the FDA officially approved the launch of Legend Bio/Johnson & Johnson's BCMA CAR-T therapy Ciltacabtagene autoleucel (cilta-cel, Cidaki Orenza, trade name Carvykti),
-
After the medical insurance negotiation, the 2021 financial report revealed the revenue generation of the two leading first-line innovative drugs
Time of Update: 2022-05-01
Figure 1: BeiGene's core financial data and indicators in 2021 (unit: thousand yuan) Data source: company announcement In 2021, BeiGene's operating income will increase by 257.
120 billion yuan in the same period last year, mainly due to the increase in sales of self-developed products and authorized products .
-
Medical Insurance Bureau: Medical insurance designated pharmacies need at least 2 licensed pharmacists
Time of Update: 2022-05-01
According to the "Notice", to apply for a "dual-channel" medical insurance designated pharmacy, eight conditions must be met, one of which requires more than two licensed pharmacists to register in the store .
-
Onslaught of eye medicine!
Time of Update: 2022-05-01
Among the new ophthalmic drugs currently under development by the company, KH906 eye drops, a class 1 new drug, has entered Phase I clinical trials for the treatment of corneal neovascularization; KH737 eye drops, which have been approved for clinical use, are used to delay the progression of myopia in children .
-
Fourth review!
Time of Update: 2022-05-01
On February 24, the official website of NMPA updated the information on the approved drugs, and the tranexamic acid injection of Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group passed the consistency evaluation .
